

GLAXOSMITHKLINE PLC

Form 6-K

July 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 July 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes ☐ No ☒

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
b) Position/status Chief Executive Officer

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

- b) Nature of the transaction  
ISIN: GB0009252882  
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£16.2250 487.325  
n/a (single transaction)

- d) Aggregated information  
Aggregated volume Price

- e) Date of the transaction 2017-07-13  
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor  
b) Position/status President, Global Manufacturing & Supply

- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793  
Details of the transaction(s): section to be repeated for (i) each type of  
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

- Ordinary shares of 25 pence  
each ('Ordinary Shares')
- a) Description of the financial instrument  
ISIN: GB0009252882  
Increase in notional interest  
in Ordinary Shares following  
the re-investment of  
dividends paid to  
shareholders on 13 July 2017,  
on Ordinary Shares held in  
the Company's Deferred  
Investment Award  
Programme.
- b) Nature of the transaction

- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£16.2250 194,930  
n/a (single transaction)

- Aggregated information  
d) A  
Aggregated volume Price

- e) Date of the transaction 2017-07-13  
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain  
b) Position/status President, Global  
Pharmaceuticals  
c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793  
Details of the transaction(s): section to be repeated for (i) each type of  
3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

- Ordinary shares of 25 pence  
each ('Ordinary Shares')
- a) Description of the financial instrument  
ISIN: GB0009252882  
Increase in notional interest  
in Ordinary Shares following
- b) Nature of the transaction

the re-investment of  
dividends paid to  
shareholders on 13 July 2017  
on Ordinary Shares held in  
the Company's Deferred  
Investment Award  
Programme.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.2250	243.662
	n/a (single transaction)	

Aggregated information  
d) A  
Aggregated volume Price

e) Date of the transaction	2017-07-13
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr B McNamara
b) Position/status	CEO, GSK Consumer Healthcare

c) Initial notification/ amendment	Initial notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

a) Description of the financial instrument	GlaxoSmithKline plc American Depositary Shares (‘ADSs’)
--	---

b) Nature of the transaction	ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's Deferred Investment Award Programme.
------------------------------	---

c) Price(s) and volume(s)	Price(s)	Volume(s)
	\$42.4750	308.094
d) Aggregated information	n/a (single transaction)	

Aggregated volume Price

- e) Date of the transaction 2017-07-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| £16.2250                 | 194.930   |
| n/a (single transaction) |           |

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2017-07-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms C Thomas

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status Senior Vice President, HR
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
3. Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument
- ISIN: GB0009252882
- Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| £16.2250                 | 194,930   |
| n/a (single transaction) |           |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2017-07-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr P J T Vallance
- b) Position/status President, R&D
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
3. Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument

	ISIN: GB0009252882						
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.						
c) Price(s) and volume(s)	<table><thead><tr><th>Price(s)</th><th>Volume(s)</th></tr></thead><tbody><tr><td>£16.2250</td><td>243.662</td></tr><tr><td colspan="2">n/a (single transaction)</td></tr></tbody></table>	Price(s)	Volume(s)	£16.2250	243.662	n/a (single transaction)	
Price(s)	Volume(s)						
£16.2250	243.662						
n/a (single transaction)							
d) Aggregated information							
Aggregated volume Price							
e) Date of the transaction	2017-07-13						
f) Place of the transaction	n/a						

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 17, 2017

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc